After U.S. markets closed for trading yesterday afternoon, The Pennant Group Inc. (PNTG:NASDAQ), which operates the Pennant group home health, hospice and senior living facilities, announced financial results for the second quarter of 2020 ended June 30, 2020. The company reported that in Q2/20 it posted GAAP diluted earnings per share of $0.15 and adjusted diluted earnings per share of $0.24.
The Pennant Group indicated that Q2/20 revenue increased by 12.1% to $92.7 million, compared to $82.7 million in Q2/19. The company added that Q2/20 GAAP earnings per share increased 15.4% to $0.15, compared to $0.13 in Q2/19 and that adjusted earnings per share increased to $0.24, compared to $0.16 in Q2/19.
The firm reported that in Q2/20, Home Health and Hospice Services revenue increased by 15.5% to $58.0 million and Senior Living Services revenue increased 6.9% to $34.8 million, compared to Q2/19.
The company stated that hospice average daily census was 1,979 in Q2/20, an increase of 18.3% over Q2/19. In addition, hospice total admissions were 1,954, total home health admissions were 5,259 and total home health Medicare admissions were 2,459 in the second quarter.
The company's CEO Daniel Walker remarked, "In the face of an unprecedented pandemic, our local leaders in both segments continued to produce strong clinical and financial results, all while sharpening our ability to navigate the complexities of the Patient Driven Groupings Model (PDGM) and continuing our spin-related transition from Ensign to Pennant systems...With our proven operating model, strong balance sheet and tremendous growth opportunities, we are stronger today than ever and poised to provide even better care to current and future patients and residents."
"In our home health and hospice business, we achieved strong financial results through consistent operational execution within our model, disciplined cost management and a continued focus on improving clinical outcomes and meeting the unique needs of each healthcare community we serve, which were made more complex by the spread of COVID-19. From the low point in mid-May, we experienced steady growth in home health total and Medicare admissions and are now seeing census trend slightly ahead of pre-COVID levels. Meanwhile, our hospice average daily census grew steadily throughout the quarter," CEO Walker added.
Derek Bunker, Pennant's chief investment officer, stated, "During the quarter and since, the company announced that it completed the acquisition of four hospice agencies and two home health agencies across Arizona, Utah and Idaho, bringing the total number of operations acquired in 2019 and since to 21. As we look to the rest of 2020 and beyond, we continue to see tremendous opportunities for acquisitions both within our footprint and in new markets."
Pennant's CFO Jennifer Freeman commented, "the company ended the second quarter with $12.1 million cash on hand and $70.0 million availability on its $75 million revolving line of credit. The company's results and cash position do not include any funds from the Provider Relief Fund established through the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which the company rejected and returned during the quarter."
The firm reaffirmed annual revenue guidance of $376-386 million and stated that its revised FY/20 earnings estimates are all based upon diluted weighted average shares outstanding of approximately 30.0 million and a 26.4% effective tax rate. The company advised that it has raised its FY/20 adjusted earnings per share guidance to a range of $0.71-0.78 and that the midpoint represents a 34.2% increase over previous midpoint guidance provided.
The Pennant Group Inc. is a holding company of independent operating subsidiaries based in Eagle, Idaho. The group stated that it "provides healthcare services through 71 home health and hospice agencies and 54 senior living communities located throughout Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming."
Pennant Group started the day with a market capitalization of around $729.5 million with approximately 27.91 million shares outstanding and a short interest of about 3.0%. PNTG shares opened almost 15% higher today at $30.00 (+$3.86, +14.77%) over yesterday's $26.14 closing price and reached a new 52-week high price today of $38.00. The stock has traded today between $27.78 and $38.00 per share and is currently trading at $36.70 (+$10.56, +40.40%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
